U.S. Consumer Services Stock News

Zimmer Biomet Holdings (NYSE:ZBH) plans to showcase advanced orthopedic technologies at AAOS 2026. The lineup includes FDA-cleared robotics, AI-supported navigation systems, smart implants, and fresh clinical data. Chief Movement Officer Arnold Schwarzenegger is scheduled to appear as a guest speaker at the event. Zimmer Biomet is a major player in musculoskeletal healthcare, with a portfolio that spans joint replacement, sports medicine, and related technologies. The AAOS 2026 announcement...

Golar LNG (NasdaqGS:GLNG) has wrapped up FY 2025 with Q4 revenue of US$132.8 million and basic EPS of US$0.10, rounding out a year in which trailing twelve month revenue sat at US$393.5 million and EPS reached US$0.64. Over the past few quarters, the company has seen revenue range from US$62.5 million in Q1 2025 to US$132.8 million in Q4 2025, with quarterly EPS moving between US$0.08 and US$0.31 across the year. This has set the backdrop for a trailing net profit margin of 18.3% compared...

American Tower (AMT) has wrapped up FY 2025 with fourth quarter revenue of US$2.7 billion, basic EPS of US$1.76 and funds from operations of US$1.3 billion, putting a clear spotlight on how its tower portfolio is translating into cash flow. Over the past few quarters, revenue has moved from US$2.6 billion in Q1 2025 to US$2.7 billion in Q4 2025. Trailing twelve month EPS sits at US$5.41 alongside US$4.2 billion of FFO, which allows investors to weigh a 23.8% net margin against the mix of...

Huron Consulting Group (HURN) closed out FY 2025 with fourth quarter revenue of US$468.6 million and basic EPS of US$1.77, against a backdrop of trailing twelve month revenue of about US$1.7 billion and EPS of US$6.02 and a reported earnings decline over the most recent year. The company has seen quarterly revenue move from US$388.4 million in Q4 2024 to US$468.6 million in Q4 2025, while basic EPS shifted from US$1.92 to US$1.77 as trailing net profit margins moved from 7.8% to 6.2%, setting...

Flywire (FLYW) just wrapped up FY 2025 with Q4 revenue of US$157.5 million and basic EPS of roughly US$0.00, capping a trailing 12 month stretch where revenue reached US$623.0 million and EPS came in at US$0.11. Over recent periods, the company has seen quarterly revenue move from US$117.6 million in Q4 2024 to US$157.5 million in Q4 2025, while basic EPS shifted from a loss of US$0.13 to near break even. This sets the stage for investors to focus closely on how margins are being managed from...

ExlService Holdings (EXLS) has wrapped up FY 2025 with fourth quarter revenue of US$542.6 million and basic EPS of US$0.38, while trailing twelve month figures show revenue at about US$2.1 billion and EPS at US$1.56, alongside 26.6% earnings growth over the past year. The company has seen quarterly revenue move from US$481.4 million in Q4 2024 to US$542.6 million in Q4 2025, with basic EPS shifting from US$0.31 to US$0.38 over the same period. This sets up a story in which improving net...

International General Insurance Holdings (NasdaqCM:IGIC) has wrapped up FY 2025 with fourth quarter total revenue of US$126.4 million and basic EPS of US$0.76, alongside trailing twelve month revenue of US$516.9 million and EPS of US$2.89. Over the past few quarters, revenue has moved from US$129 million and EPS of US$0.59 in Q1 2025 to US$132.9 million with EPS of US$0.77 in Q2, then US$128.6 million and EPS of US$0.75 in Q3, before landing at the latest Q4 figures. This gives investors a...

Forward Air (FWRD) has wrapped up FY 2025 with Q4 revenue of US$631.2 million and a basic EPS loss of US$0.91, while trailing twelve month EPS sits at a loss of US$3.51 on revenue of about US$2.5 billion. Over recent quarters the company has seen revenue move in a tight band between US$613.3 million and US$655.9 million, while basic EPS has remained in loss territory, ranging from a loss of US$0.41 to US$2.59 per quarter. For investors, this latest set of numbers keeps the spotlight firmly on...

Medline (MDLN) just posted its FY 2025 third quarter scorecard with revenue of US$7.1b, basic EPS of US$0.018, and trailing 12 month earnings growth of 33.4% alongside a net profit margin of 4.6% compared with 3.8% in the prior year. The company has seen revenue move from US$23.2b and EPS of US$0.013 in the FY 2023 trailing period to US$27.4b and EPS of roughly US$0.072 in the latest trailing 12 months. This sets the backdrop for investors to weigh earnings growth and margin expansion as the...

CS Disco (LAW) just closed out FY 2025 with Q4 revenue of US$41.2 million, a basic EPS loss of US$0.14, and a net income loss of US$8.5 million. On a trailing twelve month basis, revenue was US$156.8 million with a basic EPS loss of US$0.72 and a net income loss of US$44.4 million. The company’s quarterly revenue moved from US$36.3 million in Q3 2024 to US$41.2 million in Q4 2025, while basic EPS losses over that span ranged between US$0.42 and US$0.14 per quarter. For investors, the latest...

How Federal Signal’s FY 2025 Results Set the Tone for the Next Chapter Federal Signal (FSS) closed FY 2025 with fourth quarter revenue of US$597.1 million and basic EPS of US$1.00, alongside trailing twelve month revenue of about US$2.2 billion and EPS of US$4.06, giving investors a clear view of its recent earnings power. Over the past six reported quarters, the company has seen revenue move from US$472 million in Q4 2024 to US$597.1 million in Q4 2025. Quarterly EPS ranged from US$0.76 in...

Allot (NasdaqGS:ALLT) has wrapped up FY 2025 with Q4 revenue of US$28.4 million and basic EPS of US$0.06, alongside trailing twelve month revenue of US$102.0 million and EPS of US$0.08. Over the past few quarters, the company has reported revenue of US$24.9 million in Q4 2024, followed by US$23.2 million in Q3 2024, and then US$23.2 million, US$23.2 million, US$24.1 million, US$26.4 million and US$28.4 million across FY 2025. Over the same period, quarterly EPS moved from US$0.01 in Q4 2024...

Par Pacific Holdings (PARR) closed out FY 2025 with Q4 revenue of US$1.8 billion and basic EPS of US$1.58 on net income of US$77.7 million. Over the past four quarters, the company has reported revenue between US$1.7 billion and US$2.0 billion per quarter. Basic EPS moved from a quarterly loss of US$0.57 in Q1 2025 to a high of US$5.29 in Q3 2025, then finished at US$1.58 in Q4. For investors, that combination of solid Q4 profit and shifting EPS through the year highlights the question of how...

Solstice Advanced Materials (SOLS) has caught investor attention after a strong share price move over the past month, prompting a closer look at how its current valuation lines up with its recent financial profile. See our latest analysis for Solstice Advanced Materials. The recent move has come on top of an already strong run, with a 30 day share price return of 29.9% and a 90 day share price return of 72.8%. This suggests momentum has been building rather than fading around the current...

Atlanta Braves Holdings (BATRK) has just posted its FY 2025 third quarter numbers, with revenue of $311.5 million, basic EPS of $0.48 and net income of $30.0 million, giving investors a clear snapshot of how the season is flowing through to the bottom line. The company has seen quarterly revenue move from $282.9 million and EPS of $0.47 in Q2 FY 2024 to $290.7 million and $0.16 in Q3 FY 2024, then to $311.5 million and $0.48 in Q3 FY 2025. This sets up a narrative in which investors are...

Revolve Group (RVLV) has just posted its FY 2025 numbers, with fourth quarter revenue of US$324.4 million and basic EPS of US$0.26 on net income of US$18.6 million, capping a year where trailing twelve month revenue reached US$1.23 billion and EPS came in at US$0.87. The company has seen revenue move from US$293.7 million and EPS of US$0.17 in Q4 2024 to US$324.4 million and EPS of US$0.26 in Q4 2025, while trailing twelve month EPS stepped up from US$0.70 to US$0.87. This sets the backdrop...

Gilead Sciences (NasdaqGS:GILD) has agreed to acquire Arcellx in a $7.8b deal, expanding its presence in cell therapies for blood cancers. The acquisition adds a near-approval CAR T cell therapy candidate to Gilead’s oncology portfolio. Separately, Gilead reported new Phase 3 data for an investigational once daily, single tablet HIV regimen, showing noninferior efficacy and high tolerability versus existing treatments. For investors watching Gilead Sciences at a share price of $147.12,...

Taboola.com (TBLA) closed out FY 2025 with Q4 revenue of US$522.3 million and basic EPS of US$0.17, alongside Q4 2024 figures of US$491.0 million in revenue and basic EPS of US$0.10. Over the latest reported periods, revenue has moved from US$433.0 million in Q3 2024 to US$496.8 million in Q3 2025, while basic EPS shifted from a loss of US$0.02 to a profit of US$0.02. This highlights a story in which improving profitability and tighter margins are front and center for investors assessing this...

FrontView REIT (FVR) has just wrapped up FY 2025 with Q4 total revenue of US$16.5 million and basic EPS of a US$0.19 loss, capping a trailing twelve month stretch that totaled US$66.0 million in revenue and basic EPS of US$0.18. Over the last few reported quarters, revenue has moved from US$15.5 million in Q4 2024 to US$16.5 million in Q4 2025, while quarterly EPS has swung between earnings of US$0.19 and losses of around US$0.16 as margins absorbed a large one off loss of US$17.6 million...

BKV (BKV) closed out FY 2025 with Q4 revenue of US$330.1 million and basic EPS of US$0.76, while trailing twelve month EPS sat at US$2.00 on revenue of US$1.0 billion and net income of US$173.1 million. Over the past year, revenue has moved from US$615.1 million and a loss of US$2.00 per share on the trailing twelve month basis in Q4 2024 to US$1.0 billion and EPS of US$2.00. This frames a clear shift in reported profitability for the period. For investors, that combination of higher sales,...

Valens Semiconductor FY 2025 Earnings Snapshot Valens Semiconductor (VLN) just posted third quarter FY 2025 revenue of US$17.3 million with a basic EPS loss of US$0.07, alongside trailing twelve month revenue of US$67.9 million and a TTM basic EPS loss of US$0.29. The company has seen quarterly revenue move from US$13.6 million in Q2 2024 to US$17.3 million in Q3 2025, while quarterly EPS losses have ranged between US$0.07 and US$0.10 over the same stretch. Investors are likely to focus on...

Dine Brands Global (DIN) has laid out its FY 2025 scorecard with Q3 revenue of US$216.2 million and basic EPS of US$0.48, alongside net income of US$7.0 million, setting the tone for how the full year is shaping up. The company has seen quarterly revenue move from US$204.8 million in Q4 2024 to US$214.8 million in Q1 2025, US$230.8 million in Q2 2025, then US$216.2 million in Q3 2025. Over the same period, EPS shifted from US$0.34 to US$0.53, US$0.89 and then US$0.48. With trailing net profit...

Recursion Pharmaceuticals (RXRX) just posted another heavily loss making quarter, with Q3 FY 2025 revenue of US$5.2 million against a net loss of US$162.3 million and basic EPS of a US$0.36 loss. The company has seen quarterly revenue move between US$26.1 million in Q3 FY 2024 and US$4.5 million in Q4 FY 2024, while quarterly EPS has ranged from a US$0.34 loss to a US$0.53 loss over that period. This underscores a business that is still in investment mode rather than profit harvesting. For...

If you are wondering whether Globus Medical's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. The stock last closed at US$96.22, with returns of 6.7% over the past week, 3.5% over the past month, 10.2% year to date and 20.3% over the last year, plus 66.2% over three years and 56.4% over five years. Recent attention on Globus Medical has centered on its role in the healthcare sector and how investors are...